The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Combining CAR T-cell therapy with targeted drugs—can we improve efficacy in patients with R/R CLL?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to William Wierda, MD Anderson Cancer Center, Houston, US. We asked, Can we improve efficacy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) by combining chimeric antigen receptor (CAR) T-cell therapy with targeted drugs?

Wierda summarizes efficacy and safety findings from the TRANSCEND CLL phase I/II study on the combination of CD19-directed CAR T-cell therapy + ibrutinib in patients with R/R CLL.